Treatment-emergent AEs occurring in ≥25% of DLBCL patients (n = 16) treated with brentuximab vedotin + rituximab
| Adverse event . | Grade 1/2 . | Grade 3/4 . | Total . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Nausea | 6 | 38 | 0 | 6 | 38 | |
| Peripheral sensory neuropathy | 5 | 31 | 0 | 5 | 31 | |
| Vomiting | 5 | 31 | 0 | 5 | 31 | |
| Chills | 4 | 25 | 0 | 4 | 25 | |
| Headache | 4 | 25 | 0 | 4 | 25 | |
| Neutropenia | 1 | 6 | 3 | 19* | 4 | 25 |
| Pyrexia | 3 | 19 | 1 | 6† | 4 | 25 |